Mutational signatures: the patterns of somatic mutations hidden in cancer genomes.

Alexandrov LB, Stratton MR. · 2014

Read Mutational signatures: the patterns of somatic mutations hidden in cancer genomes. by Alexandrov LB, Stratton MR. (2014) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3990474.txt.

Introduction

Ludmil B. Alexandrov and Michael R. Stratton review patterns of mutation in cancer genomes, in Current Opinion in Genetics and Development in 2014. Each cancer starts from one cell that gains faults in its DNA and then behaves in harmful ways. Until lately, little was known about the processes that leave those faults.

New sequencing tools and new maths now let researchers sort the faults into patterns, called mutational signatures. Each signature hints at the process that made it, such as sun light damage to skin or faults in DNA repair. Light from sun, for example, leaves a known pair of base changes at set spots. The review sums up what these patterns show about how cancers arise, and how reading them may guide study of cause and growth in many tumour types.

Catalog record

CREATORAlexandrov LB, Stratton MR.
YEAR2014
COLLECTIONPAPERS
FORMATTXT
FILE SIZE53 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC3990474

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Mutational signatures: the patterns of somatic mutations hidden in cancer genomes☆ By Ludmil B Alexandrov, Michael R Stratton Published in: Current Opinion in Genetics & Development DOI: 10.1016/j.gde.2013.11.014 ABSTRACT Abstract All cancers originate from a single cell that starts to behave abnormally due to the acquired somatic mutations in its genome. Until recently, the knowledge of the mutational processes that cause these somatic mutations has been very limited. Recent advances in sequencing technologies and the development of novel mathematical approaches have allowed deciphering the patterns of somatic mutations caused by different mutational processes. Here, we summarize our current understanding of mutational patterns and mutational signatures in light of both the somatic cell paradigm of cancer research and the recent developments in the field of cancer genomics. Current Opinion in Genetics & Development 2014, 24:52–60This review comes from a themed issue on Cancer genomicsEdited by David J Adams and Ultan McDermottFor a complete overview see the Issue and the EditorialAvailable online 29th December 20130959-437X/$ – see front matter, © 2013 The Authors. Published by Elsevier Ltd. All rights reserved.http://dx.doi.org/10.1016/j.gde.2013.11.014 INTRODUCTION Long before the discovery of the double helix [1], it was well established that ultraviolet light (UV) can cause tumours of the skin [2]. While the mechanism was unclear at this time, it was hypothesized that successive doses of UV radiation result in accelerating the relative rate of cell proliferation [3]. The paradigm shifting discovery that the genetic material is contained within a deoxyribonucleic acid led to many studies in the late 1950s and throughout the 1960s examining how organisms protect their DNA from endogenous and exogenous mutations, and a focus was given to ultraviolet induced mutations (reviewed in Ref. [4•]). It was established that exposure to UV light can lead to the formation of dimers of any two adjacent pyrimidine bases on the same DNA strand with a preference for thymine–thymine dimers [4•]. It was further shown that UV irradiation damage predominantly results in cytosine to thymine or cytosine–cytosine to thymine–thymine changes, preferentially occurring at these pyrimidine dimers (i.e. C > T or CC > TT DNA mutations at dipyrimidine sites) [5,6]. This was the first detailed characterization of the pattern of DNA changes occurring due to the activity of an exogenous mutagen and, as such, the very first description of a signature of a mutational process. While these early studies established the mutational signature of UV light, it was unclear whether UV induced mutations are present and involved in the neoplastic expansion of human cancers. The development of the DNA sequencing technique with chain-terminating inhibitors by Sanger et al. [7] allowed rapid examination of the genetic material contained in cancer cells. In the early 1990s, two studies sequenced exons of the gene TP53 [8•,9•] from several patients and provided experimental evidence that aflatoxin and UV light leave distinct patterns (consistent with the ones observed in experimental systems) of DNA mutations respectively in hepatocellular and squamous-cell carcinomas. These studies confirmed that the mutational signatures of carcinogens are left as ‘evidence’ in the genomes of cancer cells [10] thus spawning research which first examined the mutations across TP53 and later across multiple genes and even whole cancer genomes in order to provide a better understanding of the mutational processes involved in human carcinogenesis. MUTATIONAL PATTERNS OF TP53 Multiple independent studies used Sanger sequencing of some (or all) exons of a cancer gene to provide clues to the aetiology of both endogenous and exogenous factors of human carcinogenesis. TP53 was usually selected for this analysis due to its high prevalence of somatic mutations in almost all tumour classes [11••]. Commonly, each of these studies involved multiple samples of a cancer type that were examined for somatic mutations in TP53 (studies reviewed in Refs. [11••,12,13]). The TP53 somatic mutations were aggregated, their spectrum was reported as specific for the given cancer type, and this spectrum was then compared to mutations generated experimentally in in vitro or in vivo systems [11••,13]. It should be noted that the mutational spectra of other genes, albeit rarely, were also used for such analysis [14]. These early studies revealed a significant heterogeneity of the TP53 spectra across different cancer types, which allowed associating some patterns of mutation to known carcinogens. Here, we provide a brief summary of some of the more important findings while details could be found in Refs. [11••,12,13]. The TP53 spectrum of skin carcinomas exhibited C > T and CC > TT mutations at dipyrimidines (all substitutions and dinucleotide substitutions are referred to by the pyrimidine(s) of the mutated Watson-Crick base pair). This was consistent with the in vitro described mutational signature of UV light. The TP53 mutational spectrum derived from lung cancers in tobacco smokers was overwhelmed by C > A substitutions, which coincided with the class of mutation produced experimentally as a result of bulky adduct formation by tobacco carcinogens on guanine [15]. In other tobacco associated cancers, such as oesophageal and head and neck tumours, C > A mutations (while still ubiquitous) were less common while there was a significant increase of T > C mutations. Interestingly, in both smokers and non-smokers, C > T and C > G mutations at non-CpG sites were elevated when compared to all other cancer types, with bladder tumours harbouring the most C > G mutations [11••]. Additionally, it was demonstrated that C > A transversions were common in hepatocellular cancers and these mutations were believed to be associated with aflatoxin, a known carcinogen commonly found in food from southern Africa and Asia [16]. Lastly, all cancer types harboured at least some C > T mutations at CpG dinucleotides (mutated base underlined), a process attributed to the normal cellular event of deamination of 5-methylcytosine [11••]. The analyses of TP53 spectra were the first attempts to bridge the gap between molecular cancer genetics and epidemiology [17]. The large number of studies examining TP53 spectra required a computational resource to facilitate and retrieve the already identified somatic mutations. At first these data were managed by the researchers that were generating it but in 1994 the International Agency for Research on Cancer (IARC) started to maintain a database while providing a free access to it [17]. The first release of the IARC TP53 database contained ∼3 000 somatic mutations [18] while the most recent version (R16) released in November of 2012, which can be found at http://p53.iarc.fr/, contains almost 30 000 somatic mutations in TP53. Though extremely informative, the data gathered from single gene studies have significant limitations. In these studies, the spectrum of a cancer type is reported by aggregating mutations from multiple samples. This may be adequate when a single mutational process generates the majority of mutations in the particular cancer (e.g. UV light is the predominant mutational process in melanoma [19••]). However, usually multiple mutational processes are operative in a single cancer sample, and combining their mutations generates a mixed composition of the patterns of somatic mutations. In most cases, reporting this jumbled spectrum is uninformative for the diversity of mutational processes operative in a single cancer type or in a single cancer sample [20••]. Moreover, the examined TP53 exons are both under selection and also have a specific nucleotide sequence. This affects the opportunity for

Read the complete text